bpc-157 human studies dosing safety review Frontiers BPC-157 For Knee Pain: Early

Description

(September 2005)

The maintenance phase drops to 25 mg once weekly for four to eight weeks to sustain the healing response at a lower dose

If the patient experiences any unwanted side effects during treatment, they should discontinue the medication and promptly inform their doctor or go to the nearest medical facility for timely management

If you want modest regenerative support as part of a broader health optimization protocol, the lower effective dose from oral administration might provide sufficient benefit